Q&A with Carol Ernst, RN — a mother of a teen
with PI

Carol Ernst is Director Consumer Advocacy PIDD at BioRx and a mother of a teenager with primary immunodeficiency.

When was your daughter diagnosed with PI?
Emily was sick from the day she was born. By the time she was a year old, we knew something was wrong. We’d see other kids crawling all over the floor, putting things in their mouths, and they’d be healthy. But it seemed like every time we went out in public, Emily would get really sick. Being a nurse, I knew something was wrong. We went to doctor after doctor, but she wasn’t diagnosed until she was 3½.

When did Emily start Ig infusions?
As soon as she was diagnosed. But the IVIg made her feel awful. She’d get really severe headaches, chills, flu-like symptoms, and nausea. Plus she still got sick with pneumonia and sinus infections when she was on the IVIg.

When did Emily start Vivaglobin® therapy?
In 2001, I met Dr. Mel Berger at an IDF breakfast. He spoke about Vivaglobin®, and I knew we needed to try it. Emily was one of the pioneers — she started on her Vivaglobin® therapy during the Vivaglobin® clinical trials.

Did you encounter any reluctance/resistance with Emily when she first started Vivaglobin therapy?
Emily was very reluctant to start therapy — even though she had such awful side effects from the IVIg. I think it was her age (10) and the fact that kids don't like change. Plus she loved her home care nurse and was afraid she would never see her again. We tried to rationalize with Emily that she needed to try this new method to see if she felt better. We were trying to not only eliminate the side effects but also to make her IgG levels more stable so she would be healthier. The first 8-10 infusions, she was not happy and not very cooperative, and she was unwilling to do any of the infusion herself.  But she soon realized that she didn’t have side effects with Vivaglobin® and she liked that very much. She also had more energy and wasn’t getting sick as much. She finally knew what it was like to feel good.

How did Emily do on Vivaglobin® therapy?
It was awesome. She was so much healthier. No pneumonia. No bad sinus infections. She went from missing 27-30 days of school a year to missing just 1-2 days a year. It changed our lives. She had more energy, and no side effects.

No injection-site reactions?
She had some redness in the beginning. Now she has none at all.

How did Vivaglobin® change your lives?
Emily became much more active. She joined the swim team and the Latin Club. She was editor of her school newspaper and graduated from high school at 16. She’s now a freshman at the University of Michigan.

When did Emily begin self-administering her therapy?
By the time she was out of the clinical trials study, she was doing all of it herself. We slowly had her do certain parts of her infusions until she got to the point where she did everything herself. We used the motivation of her going to camp for 2 weeks during one summer before she turned 13, but told her she could only go if she were able to do her infusions herself.

How have your experiences with your daughter affected your interactions with patients with PI?
I really understand what patients are going through — what their lives are like. I know they’re scared, and I try to encourage them. I use Emily’s life to motivate them.

How do you motivate patients?
I tell them, “You’re going to have the freedom and autonomy. You’re going to feel better, so you’re going to have a more active lifestyle or a better lifestyle.”

I tell them that Emily has been self-infusing since she was 13. They say, “If a 13-year-old can do it, I can do it!”

How else does your approach build patients’ confidence?
I encourage them to work through any problems they may have. I tell them we can adapt and tweak the Sub-Q self-administration process to make it work for them.

Are your patients’ experiences similar to Emily’s?
Like Emily, I find patients are healthier on Vivaglobin®, because their levels are more maintained. They have so much more energy.

If patients have problems, I encourage them to work through them. For example, if they’re infusing on their belly, we can try the legs. We can increase the number of sites. We can use numbing cream, which works great for adults. There are so many ways to make it work.

What advice can you share that might help a nurse colleague who is working with a challenging patient?
Patients are just scared. There’s nothing worse than when a patient starts off by saying, “I’m scared to death of needles.”

I try to be as open and accommodating as I can. I tell patients, “It might not go perfectly the first time, but we’ll stay with you and help you. We’ll get you through it.”

Return to Top

Next

Vol. 1, No. 6, 2009

Upcoming VITAL webcasts

Just a reminder – now you can get your VITAL nurse training via live webcast!

Please join us for the upcoming new VITAL webcast events:

  1. March 10 at 1 PM Eastern
  2. April 15 at 12 PM Eastern
  3. May 11 at 11 AM Eastern
  4. June 11 at 3 PM Eastern

These live VITAL webcasts can be viewed through an Internet browser and using a phone to dial in for the audio portion. VITAL webcasts deliver practical training on Vivaglobin®:

  1. Overview of product use
  2. Nursing considerations and responsibilities
  3. Training techniques
  4. Live question and answer session

To join in a live session, simply log onto cslbehring.conferencing.com.

Once you’ve established a live link through your Internet browser, you can dial in for the live audio by calling toll-free at 1-888-339-2306. When prompted, enter in the Meeting Number *9631744* (be sure to enter * [star] before and after the number). Use 1-205-278-7613 as an alternate number.

You can also get complete online VITAL nursing training “on demand” at www.vivaglobinaccess.com.

> Contact Us

 


The VITAL E-newsletter is designed exclusively for clinicians who are teaching patients how to use Vivaglobin® therapy. It's your source for what's happening in the world of Vivaglobin® and its impact on your patient training efforts. Be sure to look for bimonthly issues of the VITAL E-newsletter for updates and complete coverage of current and relevant topics.

Forward to a colleague Like what you’re reading? Share it with a fellow healthcare professional – especially someone who might not yet know about Vivaglobin® or the VITAL training program.

For more information about Vivaglobin®, please visit www.vivaglobin.com.

Please review our Privacy Policy and Terms of Use. To unsubscribe from this newsletter, please click here.


Important Safety Information:
Immune Globulin Subcutaneous (Human), Vivaglobin®, is indicated for the treatment of patients with primary immunodeficiency (PI).

As with all immune globulin products, Vivaglobin® is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA. If anaphylactic or anaphylactoid reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Vivaglobin® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious local site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events irrespective of causality included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.

As with all immune globulin (Ig) products, patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock. Such patients should be monitored in a clinical setting during the initial administration.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. In clinical studies, administration of Vivaglobin® has been shown to be safe and well tolerated in both adult and pediatric subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. Safety and efficacy were not studied in pediatric subjects under two years of age.

Please see full prescribing information.

CSL Behring
1020 First Avenue
PO Box 61501
King of Prussia, PA 19406-0901